Hubei Jumpcan announces share buyback to boost employee incentives

Hubei Jumpcan Pharmaceutical Co., Ltd. will repurchase company shares through centralized bidding transactions, as approved by its board of directors on November 24, 2025. The buyback aims to implement an employee stock ownership plan or equity incentive, reinforcing the company's long-term incentive mechanism.

The total repurchase amount will be no less than CNY 25 million and no more than CNY 50 million, with a maximum repurchase price of CNY 38 per share. The program is set to conclude within 12 months from the board's approval.

The company will use its own funds for the buyback. Based on the maximum repurchase price, the estimated number of shares to be repurchased ranges from 657,895 to 1,315,789 shares, representing approximately 0.07% to 0.14% of the current total share capital. The repurchase will not significantly impact the company's daily operations, financial condition, or solvency.

The board meeting, held on November 24, 2025, included all seven directors, with unanimous approval for the repurchase plan. No directors or senior executives had sold company shares within six months prior to the decision, except for chairman Cao Longxiang's tender offer acquisition and Cao Wei's exercise of stock options, ensuring no conflicts of interest or insider trading.